News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
325,417 Results
Type
Article (18709)
Company Profile (118)
Press Release (306590)
Section
Business (89013)
Career Advice (1308)
Deals (17462)
Drug Delivery (55)
Drug Development (61061)
Employer Resources (60)
FDA (9048)
Job Trends (7467)
News (173926)
Policy (15201)
Tag
Academia (1199)
Alliances (17568)
Alzheimer's disease (806)
Approvals (8998)
Artificial intelligence (52)
Bankruptcy (136)
Best Places to Work (6253)
Biotechnology (79)
Breast cancer (98)
Cancer (695)
Cardiovascular disease (57)
Career advice (1026)
Cell therapy (116)
Clinical research (49630)
Collaboration (171)
Compensation (58)
COVID-19 (2148)
Cystic fibrosis (47)
Data (729)
Diabetes (124)
Diagnostics (3197)
Earnings (51440)
Employer resources (53)
Events (51609)
Executive appointments (82)
FDA (9350)
Featured Employer (59)
Funding (170)
Gene therapy (86)
GLP-1 (524)
Government (2363)
Healthcare (9605)
Infectious disease (2183)
Inflammatory bowel disease (66)
Interviews (241)
IPO (10039)
Job creations (1447)
Job search strategy (904)
Layoffs (194)
Legal (2448)
Lung cancer (127)
Manufacturing (78)
Medical device (6259)
Medtech (6259)
Mergers & acquisitions (7490)
Metabolic disorders (333)
Neuroscience (982)
NextGen Class of 2024 (2652)
Non-profit (1834)
Northern California (778)
Obesity (205)
Opinion (84)
Parkinson's disease (50)
People (15130)
Phase I (13984)
Phase II (24512)
Phase III (15977)
Pipeline (184)
Postmarket research (1581)
Preclinical (4658)
Radiopharmaceuticals (143)
Rare diseases (110)
Real estate (1730)
Regulatory (11209)
Research institute (1155)
Resumes & cover letters (256)
Southern California (678)
Startups (1334)
United States (6628)
Vaccines (396)
Weight loss (161)
Date
Today (175)
Last 7 days (531)
Last 30 days (1862)
Last 365 days (22124)
2024 (18832)
2023 (24443)
2022 (29984)
2021 (32062)
2020 (30536)
2019 (22703)
2018 (17293)
2017 (17516)
2016 (15308)
2015 (18682)
2014 (13373)
2013 (9816)
2012 (10616)
2011 (11095)
2010 (9732)
Location
Africa (406)
Arizona (45)
Asia (21183)
Australia (3798)
California (1684)
Canada (709)
China (152)
Colorado (53)
Connecticut (73)
Europe (46969)
Florida (196)
Georgia (67)
Illinois (117)
Indiana (107)
Japan (46)
Maryland (280)
Massachusetts (1290)
Michigan (60)
Minnesota (109)
New Jersey (531)
New York (549)
North Carolina (318)
Northern California (778)
Ohio (68)
Pennsylvania (420)
South America (567)
Southern California (678)
Texas (230)
Washington State (181)
325,417 Results for "2".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Legal
GSK Settles Zantac Lawsuits for $2.2B, Analysts Now Shift Focus to Vaccines
The settlement, which is at the low end of Jefferies analysts’ $2 billion to $3.5 billion estimate, will resolve 93% of the product liability cases regarding allegations that GSK’s heartburn drug could cause cancer. Analysts say separate concerns remain about its vaccines business.
October 10, 2024
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Lundbeck Deepens Neuro, Rare Disease Portfolio With $2.6B Longboard Buy
Under the deal, the Danish pharma will gain access to Longboard’s 5-HT2C receptor superagonist that is currently in late-stage development for seizures in various developmental and epileptic encephalopathies, including Dravet syndrome.
October 14, 2024
·
2 min read
·
Tristan Manalac
Collaboration
Novartis Inks Potential $2.2B Molecular Glue Deal With Monte Rosa
The Swiss pharma is paying $150 million upfront to gain rights to Monte Rosa’s VAV1-targeting molecular glue degraders, led by a Phase I candidate which holds therapeutic promise for immune-mediated diseases.
October 28, 2024
·
2 min read
·
Tristan Manalac
Reveal Genomics® HER2DX® Genomic Test Demonstrates Significant Potential in HER2-Positive Advanced Gastric Cancer
Reveal Genomics ® HER2DX ® Genomic Test Demonstrates Significant Potential in HER2-Positive Advanced Gastric Cancer.
June 27, 2024
·
5 min read
Drug Development
IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer
IMUNON, Inc. announces database lock for its Phase 2 OVATION 2 Study evaluating the safety and efficacy of IMNN-001 in patients with advanced ovarian cancer.
June 24, 2024
·
6 min read
Cell Therapy
As 2seventy Nears Breakeven, CEO Chip Baird Explains How the Team Survived
To say that 2seventy bio’s short two years of existence have been dramatic is an understatement. CEO Chip Baird told
BioSpace
transparency and a committed staff have kept the biotech going through thick and thin.
October 2, 2024
·
8 min read
·
Annalee Armstrong
Layoffs
AN2 Therapeutics Laying Off Half Its Workforce
AN2 is discontinuing a study that evaluated epetraborole for treatment-refractory MAC lung disease and plans to shift focus to its boron chemistry platform.
August 9, 2024
·
1 min read
·
Angela Gabriel
Press Releases
Synedgen Announces $2.2 Million JWMRP Award for MIIST305 For Use as a Prophylactic Radiation Medical Countermeasure
November 1, 2024
·
4 min read
Press Releases
Cytoki Pharma Announces First Patient Dosed in Phase 2 Study of CK-0045 in Obesity and Type 2 Diabetes
November 4, 2024
·
4 min read
Press Releases
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
October 25, 2024
·
3 min read
1 of 32,542
Next
